SCHEMBL668524

SCHEMBL668524

CC(C)(C)[Si](C)(C)OCc1ccc(N)cc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.45
NR1H2 P55055 1/20 0.45
GAA P10253 3/20 0.42
TSHR P16473 2/20 0.42
GLA P06280 1/20 0.42
POLB P06746 1/20 0.42
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SRC P12931 1/20 0.33
HPGD P15428 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TLR9 Q9NR96 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18071006 0.88 GAA (0.39) IDO1NR1H2GAATSHRGLA
SCHEMBL16045315 0.85 NR1H2 (0.42) IDO1NR1H2GAATSHRGLA
SCHEMBL23287631 0.84 IDO1 (0.43) IDO1NR1H2MAPTBACE1TACR1
SCHEMBL30692344 0.82 IDO1 (0.41) IDO1GAATSHRMAPTMAPK1
SCHEMBL21163340 0.81 ALDH1A1 (0.39) GAATSHRKDM4EMEN1ALDH1A1
SCHEMBL17798345 0.79 BACE1 (0.36) IDO1GAATSHRMAPTMAPK1
SCHEMBL2596584 0.78 MAPT (0.56) IDO1GAATSHRKDM4EALDH1A1
SCHEMBL2646502 0.77 CYP1A2 (0.34) GAATSHRMAPTMAPK1HTT
SCHEMBL5462578 0.77 IDO1 (0.45) IDO1POLBBACE1TACR1
SCHEMBL30994688 0.76 GAA (0.36) GAATSHRMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648851-A1 SUBSTITUTED (HETERO)ANILINES AND THEIR USE Astrazeneca AB (SE) 2025-11-19 EP disclosed
CN-119874606-A Fused piperidinyl bicyclic and related compounds as modulators of C5a receptors 因弗拉克斯有限责任公司 2025-04-25 CN disclosed
CN-113784955-B Fused piperidinyl bicyclic and related compounds as modulators of C5a receptors 因弗拉克斯有限责任公司 2025-02-14 CN disclosed
US-12054488-B2 Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2024-08-06 US disclosed
WO-2024149728-A1 SUBSTITUTED (HETERO)ANILINES AND THEIR USE ASTRAZENECA AB (SE) 2024-07-18 WO disclosed
US-11999698-B2 Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor INFLARX GMBH (DE) 2024-06-04 US disclosed
US-11807609-B2 Deuterated compounds as immunomodulators CHEMOCENTRYX, INC. (US) 2023-11-07 US disclosed
US-11807609-B2 Deuterated compounds as immunomodulators CHEMOCENTRYX, INC. (US) 2023-11-07 US disclosed
CN-112707907-B Purine derivative and intermediate thereof, and application of purine derivative and intermediate thereof in preparation of anti-cancer drugs 张飞 2023-05-23 CN disclosed
US-20220389017-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2022-12-08 US disclosed
US-11149009-B2 Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor INFLARX GMBH (DE) 2021-10-19 US disclosed
US-20210276955-A1 DEUTERATED COMPOUNDS AS IMMUNOMODULATORS CHEMOCENTRYX, INC. 2021-09-09 US disclosed
WO-2021078141-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE 苏州锐明新药研发有限公司 2021-04-29 WO disclosed
WO-2021078141-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE 苏州锐明新药研发有限公司 2021-04-29 WO disclosed
US-20200290969-A1 FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR INFLARX GMBH (DE) 2020-09-17 US disclosed
US-20200290969-A1 FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR INFLARX GMBH (DE) 2020-09-17 US disclosed
WO-2020182384-A1 FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR INFLARX GMBH (DE) 2020-09-17 WO disclosed
WO-2020063636-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG 苏州锐明新药研发有限公司 2020-04-02 WO disclosed
US-20190144389-A1 DEUTERATED COMPOUNDS AS IMMUNOMODULATORS CHEMOCENTRYX, INC. 2019-05-16 US disclosed
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS TEIJIN PHARMA LIMITED (JP) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807609-B2 Deuterated compounds as immunomodulators C3AR1, C5AR1, C5AR2 IDO1 127/4885NR1H2 328/4885GAA 4867/4885
US-20220389017-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE PNP, ENTPD5, NTPCR IDO1 1266/4885NR1H2 3412/4885GAA 1212/4885
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS ADRB2, AGTR2, ADRB3 IDO1 3275/4885NR1H2 191/4885GAA 3030/4885
US-20190144389-A1 DEUTERATED COMPOUNDS AS IMMUNOMODULATORS C3AR1, C5AR1, C5AR2 IDO1 127/4885NR1H2 328/4885GAA 4867/4885
US-11999698-B2 Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor C5AR1, C5AR2, C3AR1 IDO1 1926/4885NR1H2 2280/4885GAA 4755/4885
US-20200290969-A1 FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR C5AR1, C5AR2, C3AR1 IDO1 1926/4885NR1H2 2280/4885GAA 4755/4885
US-20210276955-A1 DEUTERATED COMPOUNDS AS IMMUNOMODULATORS C3AR1, C5AR1, C5AR2 IDO1 127/4885NR1H2 328/4885GAA 4867/4885
US-12054488-B2 Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug PIK3CA, PIK3CD, PIK3R5 IDO1 4123/4885NR1H2 3148/4885GAA 2458/4885
US-11149009-B2 Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor C5AR1, C5AR2, C3AR1 IDO1 1926/4885NR1H2 2280/4885GAA 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.